Memantine versus Valproate in episodic migraine; a double blind randomized controlled trial

Vice Chancellor for research of Tehran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Men and women diagnosed with migraine within an age range of 18-65 and the onset of disease before their 50s; The duration of migraine is at least 1 year; at least 6 attacks per month; at least 48 hours without headache between 2 attacks; no migraine prophylaxis until inclusion
•Exclusion criteria:Renal dysfunction; Having ICDH-II criteria for medication overuse headache; Taking antipsychotics or antidepressants in last 3 months; Drug or alcohol abuse; Allergic reactions to memantine and Its compounds; Resistance to all acute migraine medications; Pain disorders; severe psychiatric disorder; Severe infections; Malignancy; Low chance of survival; Severe cardiac and vascular diseases; Neurodegenerative diseases; Pregnancy and lactation; Women in childbearing age and sexually active are included in the study, only if they receive contraception; MIDAS greater than 18

发起方

Vice Chancellor for research of Tehran University of Medical Sciences